American Heart Association 2008 Scientific Sessions: Highlights
- 12 Dec 08
- Posted on: 11/24/08
- 0 Comments
- 4324 reads
Medtronic Data Presented at American Heart Association Scientific Sessions 2008 Supports Utility of Painless Pacing Therapies in ICD Patients
New data presented at Scientific Sessions 2008 from Medtronic shows that survival among patients with implantable cardioverter defibrillators (ICDs) treated only with anti-tachycardia pacing (ATP) was superior to patients who experienced at least one shock-treated episode, further demonstrating the clinical benefit of ATP. Additionally, the analysis evaluating more than 2,000 patients found no link between inappropriate therapy and mortality, nor a causal relationship between ICD therapy (ATP or shock) and mortality.
ATP allows most patients with ICDs to receive painless pacing pulses to safely and effectively terminate dangerous ventricular tachyarrhythmias.
In the analysis, there were 3,630 treated tachyarrhythmia episodes, of which 97 percent were classified as either ventricular tachycardia (VT) or fast VT (FVT), irregular heart rhythms ranging from 100-300 beats per minute, which are treatable by an ICD. Of these episodes for which therapy was delivered, 80.2 percent were successfully treated with ATP. In fact, 91.9 percent of 2,176 treated VT episodes were successfully terminated by ATP, without the need for a shock. In addition, 68.2 percent of 1,339 treated FVT episodes were terminated by ATP, without the need for a shock.
“Today’s highly advanced ICDs can deliver both painless ATP therapy as well as a high-energy shock, if needed, to terminate dangerous heart rhythms and save lives,” said Michael O. Sweeney, MD, director, Cardiac Pacing and Implantable Device Therapies, Brigham and Women’s Hospital, and who led the analysis. “Previous studies of ATP technology have proven its ability to improve patients’ quality of life by reducing discomfort sometimes associated with life-saving shocks.”
He continued, “This new data suggests that aggressive use of ATP as part of a broad strategy to reduce shocks may not only improve patient tolerance of the therapy, but also may further enhance the life-saving benefit of ICDs beyond what has been shown in previous studies. This analysis provides further evidence that ATP should be routinely programmed in all ICD patients.”
David Steinhaus, MD, medical director for the Cardiac Rhythm Disease Management business at Medtronic, said, “These findings further demonstrate the clinical benefit to advancing pain-free therapies for patients.”
GE Launches Products, Collabora-tions, Innovation at AHA Meeting: GE Healthcare Showcases New Products in Diagnostic, Ultrasound, Invasive Cardiology Lines
At the 2008 Scientific Sessions of the American Heart Association, the company showcased new products, new relationships and, above all, a new way to look at clinical practice.
Cardiovascular Ultrasound: Three new ultrasound devices made a U.S. debut. The Vivid E9 is making the promise of true 4D heart imaging and opening the door to full cardiac studies in a completely 4D environment. Vivid q adds quantitative analysis to portable excellence, bringing even more diagnostic confidence into the equation while its intravascular ultrasound (ICE) imaging probe opens up an entirely new care area.